M2GEN’s ORIEN Avatar data product is the first solution to build comprehensive genotypic and phenotypic profiles of consenting cancer patients while shielding the patient’s identity behind an avatar.  ORIEN Avatar tracks patient clinical progressions over their lifetime to provide the richest data source for targeted cancer therapy advancement.  ORIEN Avatar data solution is optimized for oncology research by providing integrated longitudinal clinical data and whole exome, transcriptome and germline sequencing around consented oncology patients.  ORIEN Avatar enables the development of advanced cohorts based on nuanced aspects of patients’ disease including biomarkers, mutations, tumor normal, treatment progressions, recurrences and more. Learn more.

Services for Examination Analysis Research and Consultation on Health data (SEARCH) allows researchers to submit queries on the AVATAR database to M2GEN scientific data experts, with results returned in the form of a comprehensive report. 

Licensing M2GEN's AVATAR database is a great option for companies with the in-house data science expertise to maximize the investment.  Alternatively, SEARCH offers companies all of the benefits of AVATAR, helping facilitate decisions on patient stratification, biomarker discovery, and mechanisms of resistance, in a more affordable, flexible service.

Accessing annotated and linked clinicogenomic data from our exclusive, scalable network, by leveraging to data experts in oncology and bioinformatics and omics, helps you fill specific research gaps including subtyping by RNAseq, gene expression profiling, and survival analysis. Learn more.

M2GEN’s patented Total Cancer Care^® (TCC) protocol is a powerful tool that has allowed us to create the most comprehensive consented patient registries available. The TCC Active Directory puts this unique protocol to its best use by enabling our partners to design observational studies around active patient cohorts.  This active approach to data generation enables the creation of advanced cohorts and the close study of treatment efficacy and outcomes over the course of patients’ lifetimes.

Cancer research is incredibly varied and complex, requiring enormous quantities of data to advance the field. However, raw data alone isn’t enough to drive innovations and bring about new therapies. M2GEN’s biomedical informatics service makes use of the clinical and molecular data gathered through our Total Cancer Care^® protocol to deliver advanced, structured, and targeted real-world data and analysis. Our services are tailored to the specific research being conducted by our pharmaceutical partners, giving them the tools they need to develop revolutionary cancer treatments.

Through the Total Cancer Care^® protocol and ORIEN^® network, M2GEN can assist in the identification and matching of patients for clinical trials, aid in patient recruiting, development of in-silico external control arms, treatment protocol focused expanded access programs or rescuing trials in jeopardy. Our optimized site activation protocols, including submissions to a single Institutional Review Board (IRB) and scientific review committee, help to accelerate enrollment and activation. Additionally, M2GEN partners can leverage our expertise in biomedical informatics and data collection to assist with clinical trial design.

As an oncology-focused informatics company, M2GEN has the molecular pipeline analytical services and intellectual resources to coordinate and assist novel research leveraging our ORIEN network. Our services are flexible, allowing us to work closely with our partners and develop solutions that are targeted to their specific area of research. From comprehensive research coordination services to custom bioinformatics, we offer solutions to overcome the most difficult cancer research obstacles.